What's Happening?
Delphi Diagnostics has announced the publication of a study validating the Endocrine Activity Index (EAI) as a predictive biomarker for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The study, conducted as part of the GEICAM/9906
clinical trial, demonstrates that EAI can identify patients who benefit from adjuvant chemotherapy with weekly paclitaxel. The findings, published in Clinical Cancer Research, show that patients with low endocrine activity, as measured by EAI, experience improved outcomes when paclitaxel is added to anthracycline-based chemotherapy. This study builds on previous research, establishing EAI as the first genomic assay to predict the benefit of a taxane-based chemotherapy regimen in this breast cancer subtype.
Why It's Important?
The validation of EAI as a predictive biomarker represents a significant advancement in precision oncology, offering a tool for more personalized treatment strategies in breast cancer. By identifying patients who are likely to benefit from specific chemotherapy regimens, EAI can help reduce unnecessary exposure to ineffective treatments, improving patient outcomes and potentially lowering healthcare costs. This development underscores the growing role of biologically informed treatment selection in oncology, providing oncologists with actionable insights beyond traditional prognostic tests.
What's Next?
The successful validation of EAI may lead to its broader adoption in clinical settings, influencing treatment protocols for HR+/HER2- breast cancer. Delphi Diagnostics aims to make the EAI test widely available, potentially opening new pathways for personalized cancer treatment. As the healthcare industry continues to embrace precision medicine, further studies may explore EAI's applicability to other cancer types or treatment regimens, expanding its impact on oncology practice.
